基础胰岛素/胰升糖素样肽-1受体激动剂复方制剂用于治疗2型糖尿病的临床专家建议  

Expert Opinion on Fixed-ratio Combination of Basal Insulin and Glucagon-like Peptide-1 Receptor Agonist in the Management of Type 2 Diabetes

作　　者：《基础胰岛素/胰升糖素样肽-1受体激动剂复方制剂用于治疗2型糖尿病的临床专家建议》编写委员会 母义明[2] 朱大龙[3] Committee of Expert Opinion on Fixed-ratio Combination of Basal Insulin and Glucagon-like Peptide-1 Receptor Agonist in the Management of Type 2 Diabetes;Mu Yiming;Zhu Dalong(不详;Department of Endocrinology,the First Medical Center of PLA General Hospital,Beijing 100853,China;Department of Endocrinology,Drum Tower Hospital Afiliated to Nanjing University Medical School,Nanjing 210008,China)

机构地区：[1]不详 [2]解放军总医院第一医学中心内分泌科,北京100853 [3]南京大学医学院附属鼓楼医院内分泌科,南京210008

出　　处：《中华内分泌代谢杂志》2023年第8期645-650,共6页Chinese Journal of Endocrinology and Metabolism

摘　　要：我国糖尿病血糖控制达标率仍有待提高。降糖药物的疗效不佳、药物不良反应、治疗方案复杂致使患者依从性差是阻碍血糖达标的重要因素。采用机制互补的降糖药物联合方案,在增强疗效的同时减少药物不良反应,有利于患者实现并维持个体化的血糖控制目标。新型降糖药物基础胰岛素/胰升糖素样肽-1受体激动剂复方制剂具有降糖作用强、低血糖风险小、对体重影响小、注射次数少等特点。内分泌专家小组基于现有的研究证据和临床使用经验组织撰写《基础胰岛素/胰升糖素样肽-1受体激动剂复方制剂用于治疗2型糖尿病的临床专家建议》,以期为临床医生规范使用该类药物提供参考。China is striving to achieve target glycemic control.The suboptimal effectiveness of anti-hyperglycemic medications,adverse drug reactions,and poor patient compliance attributing to the complexity of treatment regimens are important factors hindering blood glucose control.New modalities with simplicity and complementary mechanism,such as fixed-ratio combination of basal insulin and glucagon-like peptide-1 receptor agonist(GLP-1RA),may address this issue.A scientific expert group was rallied with the participation of endocrinologists,based on existing research evidence and clinical experience,to provide expert opinions on the standardized use of basal insulin/GLP-1RA combination formulation in the treatment of type 2 diabetes,and to provide guidance for clinicians.

关 键 词：基础胰岛素 胰升糖素样肽-1受体激动剂 专家建议 

分 类 号：R587.1[医药卫生—内分泌]